NuVasive CEO sells 5k+ shares — 5 quick notes

Spinal Tech

NuVasive CEO Alexis V. Lukianov sold 5,313 shares of the stock in a recent transaction, according to an Inter Cooler report.

Here are five things to know about the transaction and the company's stock:

 

•    The shares were sold at an average price of $44.82, for a total value of $238,128.
•    Mr. Lukianov now directly owns 328,367 shares of the company's stock, valued at approximately $14.7 million.
•    NuVasive currently has an average rating of "buy" and a consensus price target of $52.27.
•    The company has a one-year low of $31.35 and a one-year high of $51.23.
•    NuVasive's market cap is $2.136 billion.

More articles on devices:

FDA approves Tornier's shoulder system, aims to improve shoulder arthroplasty — 4 things to know
Piper Jaffray assumes Integra LifeSciences coverage — 5 things to know
Zimmer sells $7.65B of senior notes for Biomet merger — 7 key notes

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers